SLGL
Sol-Gel Technologies Ltd. NASDAQ$77.70
Mkt Cap $218.3M
52w Low $4.11
78.4% of range
52w High $97.97
50d MA $79.21
200d MA $47.84
P/E (TTM)
-34.4x
EV/EBITDA
-14.3x
P/B
9.2x
Debt/Equity
0.0x
ROE
-26.9%
P/FCF
426.9x
RSI (14)
—
ATR (14)
—
Beta
1.27
50d MA
$79.21
200d MA
$47.84
Avg Volume
42.2K
About
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of a…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 19, 2026 | BMO | 0.39 | -1.07 | -374.4% | 75.34 | -0.4% | +8.5% | -3.1% | -12.1% | +6.2% | +5.0% | — |
| Nov 20, 2025 | BMO | -2.09 | -2.13 | -1.9% | 36.04 | +3.2% | -0.8% | +1.7% | +15.9% | +12.1% | +12.9% | — |
| Aug 15, 2025 | BMO | -0.67 | 4.17 | +722.4% | 15.25 | -0.2% | +1.2% | +5.6% | +16.3% | +20.7% | +69.2% | — |
| Apr 29, 2025 | BMO | -1.10 | -2.10 | -90.9% | 8.12 | +1.0% | +4.8% | -6.4% | -4.7% | -10.1% | -45.6% | — |
| Mar 26, 2025 | BMO | -0.11 | -0.21 | -90.8% | 5.59 | +0.2% | +0.0% | -5.4% | -1.6% | -7.0% | -12.2% | — |
| Nov 15, 2024 | BMO | -0.13 | -0.01 | +92.3% | 5.00 | +13.8% | +3.0% | -2.4% | -13.8% | -11.8% | -5.0% | — |
| Aug 16, 2024 | BMO | -0.20 | 0.07 | +135.0% | 4.20 | +0.0% | +2.6% | +11.9% | +6.9% | +42.9% | +65.5% | — |
| May 20, 2024 | BMO | -0.15 | -0.23 | -53.3% | 7.50 | -6.7% | -6.0% | +6.7% | +5.3% | +6.7% | +6.7% | — |
| Mar 13, 2024 | BMO | -0.16 | -0.17 | -6.2% | 10.60 | -1.9% | +0.0% | -0.9% | -1.9% | -1.9% | -7.4% | — |
| Nov 9, 2023 | BMO | -0.23 | -0.21 | +8.7% | 14.40 | +2.1% | +3.5% | -4.2% | +1.4% | +0.0% | +2.1% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $69.50 | $69.98 | +0.7% | +3.7% | -9.3% | -17.3% | -15.9% | -17.5% |
| Dec 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $42.16 | $43.11 | +2.3% | +0.0% | +2.4% | +3.2% | -0.7% | +5.6% |
| Oct 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $39.00 | $40.94 | +5.0% | +2.1% | -5.5% | -5.1% | -5.1% | -11.5% |
| Aug 19 | Raymond James | Downgrade | Strong Buy → Outperform | — | $4.31 | $4.41 | +2.3% | +9.0% | +4.2% | +39.2% | +61.3% | +49.9% |
| May 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.00 | $8.26 | +3.2% | -1.2% | +0.0% | +0.0% | +0.6% | -2.5% |
| May 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.50 | $7.00 | -6.7% | -6.0% | +6.7% | +5.3% | +6.7% | +6.7% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.80 | $13.50 | -2.2% | +5.8% | +4.3% | +6.5% | +9.8% | +2.2% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $29.00 | $29.20 | +0.7% | +5.2% | -3.8% | -6.6% | -1.0% | -5.2% |
| Aug 11 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $32.10 | $31.30 | -2.5% | -9.7% | -5.0% | -13.1% | -15.6% | -10.6% |
| Jul 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $39.40 | $40.00 | +1.5% | -1.5% | -8.9% | -8.9% | -7.4% | -7.4% |
Data updated apr 27, 2026 1:39am
· Source: massive.com